Nurix Therapeutics (NRIX) Treasury Shares (2019 - 2020)

Nurix Therapeutics (NRIX) has reported Treasury Shares for 8 consecutive years, with $3.1 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Treasury Shares rose 3.13% year-over-year to $3.1 million; the TTM figure through May 2026 stood at $3.1 million (up 3.13% YoY), while the FY2025 annual figure was $2.2 million, up 14.82% from the prior year.
• Treasury Shares eased to $3.1 million in Q2 2026 per NRIX's latest filing, from $3.4 million in the prior quarter.
• Across five years, Treasury Shares topped out at $3.4 million in Q1 2026 and bottomed at $649382.0 in Q1 2022.
• Historically, Treasury Shares has averaged $1.9 million across 5 years, with a median of $2.0 million in 2024.
• Annual changes were most pronounced in 2022 — Treasury Shares soared 3824.12% — and 2026, when it advanced 3.13%.
• Nurix Therapeutics' Treasury Shares stood at $784824.0 in 2022, then soared by 58.77% to $1.2 million in 2023, then surged by 56.98% to $2.0 million in 2024, then increased by 14.82% to $2.2 million in 2025, then jumped by 36.69% to $3.1 million in 2026.
• Business Quant data shows NRIX's Treasury Shares at $3.1 million in Q2 2026, $3.4 million in Q1 2026, and $2.2 million in Q4 2025.